Sinopharm Tech Holdings Limited (SINOPHARM TECH) filed its Monthly Return for the period ended 30 June 2026, confirming a stable capital structure with no movements in authorised, issued or treasury shares during the month.

Authorised / Registered Capital • Ordinary shares: 12.80 billion authorised at HKD 0.0125 par value, representing HKD 160.00 million of authorised capital. • Non-voting convertible preference shares: 3.20 billion authorised at the same HKD 0.0125 par value, equal to HKD 40.00 million. • Total authorised capital remained unchanged at HKD 200.00 million. (The current structure follows the capital reorganisation approved in August 2024 and effected in November 2024.)

Issued Shares and Public Float • Ordinary shares in issue: 633.69 million (unchanged versus May 2026). • Treasury shares: none. • The company confirmed compliance with the minimum 25% public-float requirement under GEM Rule 17.37D(1).

Preference Shares and Potential Dilution • Issued non-voting convertible preference shares (CPS): 1.48 billion, unchanged during June. • These CPS—issued in November 2024 under loan capitalisation agreements—are convertible into ordinary shares on a 1:1 basis at HKD 0.10 per share over a 10-year period, representing a potential 234% dilution to the existing ordinary share base if fully converted. • Total nominal amount of CPS outstanding: HKD 148.02 million.

Equity Incentives • 2021 Share Option Scheme: 4.96 million options outstanding, exercisable through 30 June 2028 at an adjusted exercise price of HKD 1.00. No options were exercised, lapsed, or granted in June. • The scheme still allows issuance of up to 12.42 million ordinary shares upon future option grants and exercises.

Liquidity and Capital Outlook With no share issuance, redemption or repurchase activity in June, Sinopharm Tech’s share capital structure, public-float status, and potential fully-diluted share count are unchanged from the prior month. Confirmation of rule compliance and the absence of new equity inflows or outflows highlight a period of capital stability for the company.